Weixue Wang
Senior Director Antares Therapeutics
Weixue Wang is the Senior Director of Biochemistry at Antares Therapeutics. He joined Scorpion Therapeutics in 2021, where he established the company’s biochemistry capability and directly contributed to the discovery of multiple development candidates and clinical assets, including STX-478, which was acquired by Eli Lilly in 2025. Following the acquisition, he transitioned to Scorpion’s spin-out successor, Antares. Over an industry career that also includes tenure at Johnson & Johnson, his work has focused on leveraging mechanistic biochemistry, biophysics, cellular pharmacology, and assay development to drive small-molecule drug discovery across covalent, non-covalent, and degrader modalities. Weixue holds a Ph.D. in Biophysics from the University of Illinois Urbana-Champaign and completed postdoctoral training at MIT. He was named one of Chemical & Engineering News’ “Talented 12” by the American Chemical Society in 2022.
Seminars
Covalent development generates complex kinetic and selectivity data that are often difficult to reconcile across assays and systems. This workshop will focus on how kinact/KI, target engagement and selectivity readouts can be integrated to build translational readiness, supporting clearer alignment between discovery data, PK/PD strategy and downstream development planning.
This session will address:
• Assessing how kinetic, selectivity and target engagement data can be integrated across biochemical and cellular systems to build a consistent view of covalent behavior
• Comparing approaches to generating and contextualizing kinact/KI measurements, including their applicability and limitations across enzyme and non‑enzyme targets
• Linking kinetic and selectivity profiles with early safety and PK/PD considerations to support translational planning and downstream development strategy
